Regulatory Hurdles in M&A: What Founders Need to Know
Most founders think selling a business is about finding the right buyer, negotiating price, and getting to closing.
That’s only part of the equation.
What often catches founders off guard are the regulatory hurdles that sit between signing and closing—issues that can delay, complicate, or even derail an otherwise strong deal.
Because once a transaction reaches a certain size or involves certain industries, it’s no longer just a private agreement between buyer and seller.
It becomes a matter of compliance.
And compliance introduces scrutiny.
Why Regulation Exists in M&A
Regulatory oversight in M&A isn’t arbitrary.
It’s designed to protect broader interests:
- Market competition
- Consumers
- National security
- Industry stability
From a founder’s perspective, this can feel like friction.
From a regulatory perspective, it’s about preventing outcomes that could harm markets or the public.
Understanding this distinction matters—because it shapes how regulators approach your deal.
Antitrust Review: The Most Common Hurdle
One of the most common regulatory checkpoints is antitrust review.
In the U.S., this is typically handled under the Hart-Scott-Rodino (HSR) Act for deals that meet certain size thresholds.
The goal is simple:
Determine whether the transaction would reduce competition in a meaningful way.
If regulators believe it might, they can:
- Request additional information
- Delay the transaction
- Require concessions (such as divestitures)
- Block the deal entirely
For founders, the key takeaway is this:
Even if your deal seems straightforward, it may still require regulatory clearance.
Timing Implications of Regulatory Approval
Regulatory review introduces time.
And time introduces risk.
Once a deal is signed, there’s often a waiting period while regulators review the transaction.
This can range from:
- A few weeks for straightforward cases
- Several months for more complex reviews
During this time:
- The business must continue operating normally
- Market conditions may change
- Buyer and seller expectations can shift
This is why timing isn’t just about closing quickly—it’s about planning for the reality of regulatory processes.
Industry-Specific Regulations
Certain industries face additional layers of oversight.
For example:
- Healthcare
- Financial services
- Telecommunications
- Energy
These sectors often require:
- Specific approvals
- Licensing transfers
- Compliance reviews
In some cases, multiple agencies may be involved.
This increases both complexity and timeline.
If your business operates in a regulated industry, these hurdles should be anticipated early—not discovered mid-process.
Cross-Border Considerations
If your transaction involves an international buyer, regulatory complexity increases.
Now you’re dealing with:
- Multiple jurisdictions
- Different regulatory bodies
- Varying standards for approval
For example:
- U.S. deals may involve CFIUS review for national security concerns
- European transactions may require EU competition approval
- Other countries may impose their own requirements
Each jurisdiction adds another layer of review—and another potential point of delay.
National Security Reviews (CFIUS)
In the U.S., the Committee on Foreign Investment in the United States (CFIUS) reviews certain transactions involving foreign buyers.
The focus is national security.
This is particularly relevant if your business:
- Handles sensitive data
- Operates in critical infrastructure
- Develops advanced technologies
Even if your company doesn’t appear sensitive on the surface, certain elements—like data access—can trigger review.
CFIUS has the authority to:
- Require mitigation measures
- Delay closing
- Or block transactions entirely
This is not a theoretical risk—it’s a real consideration in cross-border deals.
The Risk of “Second Requests”
In antitrust reviews, one of the biggest delays comes from what’s known as a second request.
This is when regulators ask for extensive additional information before approving a deal.
Second requests can require:
- Detailed financial data
- Internal communications
- Market analysis
Responding to them can take months.
And during that time, the deal is effectively paused.
While not every transaction triggers a second request, founders should understand that it’s a possibility—especially in competitive industries.
Conditions and Concessions
Approval isn’t always binary.
Sometimes regulators approve a deal with conditions.
These might include:
- Divesting certain business units
- Limiting certain operations
- Agreeing to behavioral restrictions
From a founder’s perspective, this can impact:
- Final deal value
- Strategic rationale
- Post-close operations
It’s important to understand that regulatory approval may come with trade-offs.
Confidentiality and Disclosure Requirements
M&A deals are typically confidential.
Regulatory processes can change that dynamic.
Certain filings require:
- Disclosure of transaction details
- Submission of sensitive information
- Coordination across multiple parties
While confidentiality is still maintained to a degree, the process introduces additional complexity around information sharing.
The Importance of Early Assessment
One of the biggest mistakes founders make is assuming regulatory approval will be straightforward.
Then discovering late in the process that:
- Approval is required
- Timelines are longer than expected
- Additional conditions may apply
Early assessment allows you to:
- Identify potential hurdles
- Build realistic timelines
- Align expectations with the buyer
This reduces the risk of surprises.
Structuring Deals With Regulation in Mind
In some cases, deal structure can influence regulatory outcomes.
For example:
- Carving out certain business units
- Adjusting transaction scope
- Sequencing transactions differently
These strategies can help address regulatory concerns proactively.
But they require planning.
Once the deal is fully structured and agreed upon, flexibility decreases.
Coordination Across Advisors
Regulatory issues sit at the intersection of:
- Legal
- Strategic
- Operational
That means coordination is critical.
Your team may include:
- M&A advisors
- Legal counsel
- Regulatory specialists
If these groups aren’t aligned, issues can arise.
At Legacy Advisors (https://legacyadvisors.io/), we work closely with founders to ensure regulatory considerations are part of the broader deal strategy—not an afterthought.
Learning From Experience
On the Legacy Advisors Podcast (https://legacyadvisors.io/podcast), we’ve discussed how many deals don’t fail because of price.
They fail because of process.
Regulatory hurdles are a key part of that process.
The founders who navigate them successfully are the ones who:
- Understand the landscape
- Plan for delays
- Engage the right advisors early
The Bigger Picture: Regulation Is Part of the Deal
It’s easy to view regulation as an obstacle.
But in reality, it’s part of the transaction environment.
Ignoring it doesn’t make it go away.
It just increases the likelihood of disruption.
The most effective founders treat regulatory considerations as:
- Predictable
- Manageable
- And plan-worthy
Final Thoughts
Selling your business isn’t just about finding a buyer and agreeing on price.
It’s about navigating everything that happens between signing and closing.
Regulatory hurdles are a key part of that journey.
They can:
- Delay deals
- Change deal terms
- Or stop transactions altogether
But with the right preparation, they can be managed.
This is a theme I reinforce in The Entrepreneur’s Exit Playbook (https://amzn.to/40ppRpT):
The best outcomes aren’t accidental.
They’re designed.
If you’re preparing for a transaction and want to ensure you’re accounting for all aspects of the process—including regulatory considerations—visit https://legacyadvisors.io/
Because in M&A, the deal doesn’t end when you agree on terms.
It ends when you close.
Frequently Asked Questions About Regulatory Hurdles in M&A: What Founders Need to Know
How do I know if my deal will require regulatory approval?
It depends on a combination of factors—primarily deal size, industry, and the parties involved.
In the U.S., transactions above certain thresholds may require filing under the Hart-Scott-Rodino (HSR) Act, which triggers antitrust review. Beyond size, your industry plays a major role. Sectors like healthcare, financial services, energy, and technology often face additional scrutiny.
If there’s a foreign buyer involved, that can introduce another layer, such as CFIUS review for national security concerns.
The safest approach is to assume regulatory review may be required and have your advisors evaluate this early. Waiting until after signing to assess regulatory obligations can lead to delays and surprises that could have been anticipated.
How long do regulatory approvals typically take?
There’s no single answer—it varies based on the complexity of the deal.
For straightforward transactions, regulatory clearance can take a few weeks. However, more complex deals—especially those involving competitive markets or cross-border elements—can take several months or longer.
If a deal triggers a “second request” in an antitrust review, timelines can extend significantly. These requests require detailed information and can pause the process while both sides respond.
The key is building realistic expectations into your timeline. Founders who plan for regulatory review as part of the process—not an exception—are better positioned to manage delays without disrupting the deal.
Can regulatory issues actually kill a deal?
Yes—and it happens more often than founders expect.
If regulators determine that a transaction reduces competition, creates market concentration, or poses national security risks, they have the authority to block it. In other cases, they may impose conditions that make the deal less attractive or financially viable.
Even when deals aren’t outright blocked, prolonged delays or required concessions can cause one party to walk away.
That’s why early assessment is critical. Identifying potential regulatory risks upfront allows you to adjust strategy, structure, or expectations before significant time and resources are invested.
What is a “second request,” and why does it matter?
A second request is an in-depth follow-up inquiry from regulators during antitrust review.
Instead of approving a deal during the initial waiting period, regulators request extensive additional information. This can include internal communications, financial data, market analysis, and competitive positioning.
Responding to a second request is time-consuming and resource-intensive. It can delay the transaction by months and significantly increase legal and advisory costs.
For founders, it’s important to understand that a second request doesn’t mean the deal will be blocked—but it does mean the process becomes more complex and uncertain. Preparing for this possibility helps manage expectations and timelines.
How can founders prepare for regulatory hurdles early?
Preparation starts with awareness and early involvement of the right advisors.
Before going to market—or at least before signing an LOI—you should:
- Assess whether your deal may trigger regulatory review
- Understand industry-specific requirements
- Evaluate potential cross-border implications
- Build realistic timelines that account for approvals
It’s also important to align your advisory team early. Legal, M&A, and regulatory specialists should be working together from the outset.
The founders who navigate regulatory hurdles successfully don’t treat them as surprises—they treat them as part of the process and plan accordingly.